MA41216A - Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine - Google Patents

Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine

Info

Publication number
MA41216A
MA41216A MA041216A MA41216A MA41216A MA 41216 A MA41216 A MA 41216A MA 041216 A MA041216 A MA 041216A MA 41216 A MA41216 A MA 41216A MA 41216 A MA41216 A MA 41216A
Authority
MA
Morocco
Prior art keywords
trioxacarcin
analogues
preparation
total synthesis
synthesis
Prior art date
Application number
MA041216A
Other languages
English (en)
Inventor
Quan Cai
Kyriacos C Nicolaou
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of MA41216A publication Critical patent/MA41216A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA041216A 2014-12-19 2015-12-17 Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine MA41216A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094662P 2014-12-19 2014-12-19
US201562186128P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
MA41216A true MA41216A (fr) 2017-10-24

Family

ID=56127867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041216A MA41216A (fr) 2014-12-19 2015-12-17 Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine

Country Status (23)

Country Link
US (1) US10899773B2 (fr)
EP (1) EP3233877A4 (fr)
JP (1) JP2017537968A (fr)
KR (1) KR20170122718A (fr)
CN (1) CN107250144A (fr)
AU (1) AU2015364347A1 (fr)
BR (1) BR112017013194A2 (fr)
CA (1) CA2970955A1 (fr)
CL (1) CL2017001599A1 (fr)
CO (1) CO2017007074A2 (fr)
CR (1) CR20170331A (fr)
DO (1) DOP2017000144A (fr)
EA (1) EA201791388A1 (fr)
EC (1) ECSP17046657A (fr)
GT (1) GT201700139A (fr)
HK (1) HK1243422A1 (fr)
IL (1) IL252947A0 (fr)
MA (1) MA41216A (fr)
MX (1) MX2017008162A (fr)
PE (1) PE20171787A1 (fr)
PH (1) PH12017501147A1 (fr)
SG (1) SG11201704935XA (fr)
WO (1) WO2016100833A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210230178A1 (en) * 2017-08-17 2021-07-29 William Marsh Rice University Trioxacarcin analogs and dimers as potent anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815995A (ja) 1981-07-22 1983-01-29 Kyowa Hakko Kogyo Co Ltd Dc−45−a↓1およびdc−45−a↓2ならびにそれらの製造法
EP0157203A3 (fr) * 1984-04-04 1986-10-01 American Cyanamid Company Agents antitumoraux LL-D49194 alpha 1, LL-D49194 bêta 1, LL-D49194 bêta 2, LL-D49194 bêta 3, LL-D49194 gamma, LL-D49194 delta, LL-D49194 epsilon, LL-D49194 dzéta, LL-D49194 êta LL-D499194 oméga 1, LL-D49194 oméga 2 et LL-D49194 oméga 3
JPS63135389A (ja) * 1986-11-26 1988-06-07 Kyowa Hakko Kogyo Co Ltd Dc−45類の誘導体
WO2011119549A1 (fr) 2010-03-22 2011-09-29 President And Fellows Of Harvard College Trioxacarcines et utilisations de celles-ci
US9775915B2 (en) * 2012-11-26 2017-10-03 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof

Also Published As

Publication number Publication date
BR112017013194A2 (pt) 2018-01-02
EA201791388A1 (ru) 2017-11-30
EP3233877A2 (fr) 2017-10-25
EP3233877A4 (fr) 2018-10-17
HK1243422A1 (zh) 2018-07-13
AU2015364347A1 (en) 2017-07-13
SG11201704935XA (en) 2017-07-28
CN107250144A (zh) 2017-10-13
WO2016100833A3 (fr) 2017-01-05
CO2017007074A2 (es) 2017-10-20
GT201700139A (es) 2018-10-24
PH12017501147A1 (en) 2018-03-05
JP2017537968A (ja) 2017-12-21
US10899773B2 (en) 2021-01-26
PE20171787A1 (es) 2017-12-28
DOP2017000144A (es) 2017-09-29
ECSP17046657A (es) 2019-03-29
CL2017001599A1 (es) 2018-11-09
WO2016100833A2 (fr) 2016-06-23
KR20170122718A (ko) 2017-11-06
US20190023717A1 (en) 2019-01-24
MX2017008162A (es) 2018-03-06
CA2970955A1 (fr) 2016-06-23
CR20170331A (es) 2017-11-17
IL252947A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MA46180A (fr) Analogues de l'amyline
EP3302275A4 (fr) Indication d'états physiologiques selon la sudation
EP3174874A4 (fr) Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants
HUE055458T2 (hu) Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére
ZA201703834B (en) Oral care compositions and methods of use
EP3271352A4 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
MA49715A (fr) Oligomères et conjugués d'oligomères
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
EP3160970A4 (fr) Synthèse d'analogues d'halochondrines et leurs utilisations
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
EP3357485A4 (fr) Cosmétique d'écran solaire
SG10202004071UA (en) Cryoprecipitate compositions and methods of preparation thereof
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés
EP3393459A4 (fr) Compositions de nanoémulsion de fluorocarbure et procédés de préparation et d'utilisation associés
ZA201801015B (en) Oral care compositions and methods of using the compositions
EP3407974A4 (fr) Analogues d'amlexanox
EP3344280A4 (fr) Formation d'os
EP3357483A4 (fr) Cosmétique d'écran solaire
DK3319980T3 (da) Formuleringer til forbedring af virkningen af hydrofobe lægemidler
IL267279A (en) Pharmaceutical formulations of suvorexant
EP3387469A4 (fr) Détermination d'électrofaciès
PT3236938T (pt) Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol
IL258304A (en) Oral care compounds and methods for using the compounds